文献速递泌尿生殖腹部US

对比增强超声对不确定性肾脏肿物患者临床管理的影响:来自2家机构的回顾性分析

Effects of Contrast-Enhanced Ultrasound of Indeterminate Renal Masses on Patient Clinical Management: Retrospective Analysis From 2 Institutions.
PubMed 文献 · J Ultrasound Med · 2020-07-13

该回顾性研究分析了2家学术医学中心2014年1月1日至2018年12月31日期间因慢性肾病或既往肾切除史、对未经治疗的肾脏肿物行对比增强超声(CEUS)的157例患者共215个病灶。CEUS为71.6%的病灶提供了最终治疗建议,其中76.6%判为良性无需随访,且无一例 later 发生肾细胞癌;判为恶性直接手术者病理确诊率为87.5%。研究结论强调CEUS对不确定性肾脏肿物临床治疗的影响,包括减少潜在肾毒性对比剂的使用并提供直接移植通路。

要点

  • CEUS可为71.6%的不确定性肾脏肿物提供最终治疗建议。
  • CEUS判为良性无需随访的病灶中无一例 later 发生肾细胞癌。
  • CEUS判为恶性直接手术者病理确诊率为87.5%。

核心结论

  • CEUS对不确定性肾脏肿物的临床治疗有影响,包括减少潜在肾毒性对比剂的使用并提供直接移植通路。

研究设计与样本

  • 回顾性研究,纳入2家学术医学中心2014年1月1日至2018年12月31日期间连续接受肾脏CEUS的患者,共分析157例患者215个病灶;纳入条件为有记录的慢性肾病(估算肾小球滤过率<60 mL/min/1.73 m2)或既往肾切除史且因既往未治疗的肾脏肿物接受CEUS。

诊断标准与关键数值

  • CEUS为71.6%(154/215)的病灶提供了最终治疗建议。
  • 在154个有最终治疗建议的病灶中,7.8%(12/154)虽CEUS提示恶性但失访,15.6%(24/154)直接接受手术干预且病理确诊恶性占87.5%(21/24),其余76.6%(118/154)判为良性无需额外随访。
  • 118个CEUS判为良性无需随访的病灶中无一例 later 出现肾细胞癌证据,仅5.1%(6/118)因该肿物被转诊进一步横断面成像。
  • 28.4%(61/215)的病灶CEUS建议6至12个月间隔 surveillance 成像,其中不到10%(6/61)在建议的CEUS后6个月内接受了额外横断面成像。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the long-term impact of contrast-enhanced ultrasound (CEUS) on the treatment of patients with indeterminate renal masses.

METHODS: In this retrospective study, consecutive charts of all patients receiving renal CEUS at 1 of 2 academic medical centers between January 1, 2014, and December 31, 2018, were reviewed. Patients were included in the study if they had documented chronic renal disease (estimated glomerular filtration rate < 60 mL/min/1.73 m2 ) or prior nephrectomy and received CEUS for a previously untreated renal mass.

RESULTS: A total of 215 lesions in 157 patients were used for analysis. Contrast-enhanced ultrasound provided a final treatment recommendation in 71.6% of lesions (154 of 215). Of these 154 lesions, 7.8% (12 of 154) were lost to follow-up despite CEUS suggesting malignancy; 15.6% (24 of 154) went directly for surgical intervention, with malignancy confirmed by pathologic results in 87.5% (21 of 24) of these cases; and the remaining 76.6% (118 of 154) were deemed benign and required no additional follow-up. Of the 118 lesions diagnosed by CEUS as benign and requiring no follow-up, none showed evidence of later renal cell carcinoma development and, only 5.1% (6 of 118) of the total population was referred for further cross-sectional imaging of the mass in question. In 28.4% of all lesions (61 of 215), CEUS resulted in a recommendation for surveillance imaging at a 6- to 12-month interval, and less than 10% (6 of 61) of these underwent additional cross-sectional imaging within the recommended 6 months after CEUS.

CONCLUSIONS: These findings highlight the impact of CEUS on clinical treatment of indeterminate renal masses, including reducing the use of the potentially nephrotoxic contrast agents and providing a direct pathway to transplant.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Eisenbrey JR, Kamaya A, Gummadi S, et al. Effects of Contrast-Enhanced Ultrasound of Indeterminate Renal Masses on Patient Clinical Management: Retrospective Analysis From 2 Institutions. J Ultrasound Med. 2020. PMID: 32657452. doi:10.1002/jum.15383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。